Recent Updates — CLDX

Celldex Therapeutics announced positive topline results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials of barzolvolimab in chronic spontaneous urticaria (CSU). Both studies met their primary endpoint of mean change from baseline in weekly urticaria activity score at Week 12, as well as all key secondary endpoints. The drug demonstrated statistically significant improvements across both the 150 mg and 300 mg dose groups compared to placebo, with high rates of complete response observed in patients refractory to omalizumab and those with severe disease or angioedema. Barzolvolimab showed a favorable safety profile through Week 24. The company plans to submit a Biologics License Application to the FDA in 2027. Celldex Therapeutics is a biopharmaceutical company developing novel antibody-based treatments for allergic, inflammatory, and autoimmune disorders.

Sam Martin, Senior Vice President and Chief Financial Officer of Celldex Therapeutics, Inc. notified the Company of his plans to retire in March 2027. The Company has initiated a search for a new Chief Financial Officer to ensure a smooth transition. Celldex Therapeutics, Inc. is a biotechnology company that develops clinical-stage drug candidates for the treatment of various oncology-related diseases.

At the 2026 Annual Meeting of Stockholders held on June 25, 2026, Celldex Therapeutics, Inc. stockholders approved an amendment to the 2021 Omnibus Equity Incentive Plan to increase the number of shares available for issuance by 3,400,000, bringing the total to 12,900,000 shares. The meeting also resulted in the election of nine directors to the board, the ratification of PricewaterhouseCoopers LLP as the independent auditor, and an advisory vote on executive compensation. Celldex Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for cancer and inflammatory diseases.